Book contents
- Maternal Hemodynamics
- Maternal Hemodynamics
- Copyright page
- Contents
- Contributors
- Section 1 Physiology of Normal Pregnancy
- Section 2 Pathological Pregnancy: Screening and Established Disease
- Section 3 Techniques: How To Do
- Section 4 Cardiovascular Therapies
- Chapter 15 Treatment Options for Hypertension in Pregnancy
- Chapter 16 Aspirin
- Chapter 17 Vascular Endothelial Growth Factor Gene Therapy in the Management of Cardiovascular Problems in Pregnancy
- Chapter 18 Nitric Oxide Donors in Preeclampsia
- Chapter 19 Vasodilatation and Fluid Expansion
- Section 5 Controversies
- Index
- Plate Section (PDF Only)
- References
Chapter 18 - Nitric Oxide Donors in Preeclampsia
from Section 4 - Cardiovascular Therapies
Published online by Cambridge University Press: 28 April 2018
Book contents
- Maternal Hemodynamics
- Maternal Hemodynamics
- Copyright page
- Contents
- Contributors
- Section 1 Physiology of Normal Pregnancy
- Section 2 Pathological Pregnancy: Screening and Established Disease
- Section 3 Techniques: How To Do
- Section 4 Cardiovascular Therapies
- Chapter 15 Treatment Options for Hypertension in Pregnancy
- Chapter 16 Aspirin
- Chapter 17 Vascular Endothelial Growth Factor Gene Therapy in the Management of Cardiovascular Problems in Pregnancy
- Chapter 18 Nitric Oxide Donors in Preeclampsia
- Chapter 19 Vasodilatation and Fluid Expansion
- Section 5 Controversies
- Index
- Plate Section (PDF Only)
- References
- Type
- Chapter
- Information
- Maternal Hemodynamics , pp. 181 - 192Publisher: Cambridge University PressPrint publication year: 2018
References
Poston, L. Endothelial dysfunction in pre-eclampsia. Pharmacol Rep 2006;58:69–74.Google ScholarPubMed
Roberts, JM, Hubel, CA. The two stage model of preeclampsia: variations on the theme. Placenta 2009;30:32–7.Google Scholar
Savvidou, MD, Hingorani, AD, Tsikas, D, Frölich, JC, Vallance, P, Nicolaides, KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003;361:1511–7.Google Scholar
López-Alarcón, M, Montalvo-Velarde, I, Vital-Reyes, VS, Hinojosa-Cruz, JC, Leaños-Miranda, A, Martínez-Basila, A. Serial determinations of asymmetric dimethylarginine and homocysteine during pregnancy to predict pre-eclampsia: a longitudinal study. BJOG 2015;122:1586–92.CrossRefGoogle ScholarPubMed
Koga, K, Osuga, Y, Yoshino, O, Hirota, Y. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348–51.CrossRefGoogle ScholarPubMed
Krauss, T, Pauer, H-U, Augustin, HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004;23:101–11.CrossRefGoogle ScholarPubMed
Romero, R, Nien, JK, Espinoza, J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:9–23.CrossRefGoogle ScholarPubMed
Venkatesha, S, Toporsian, M, Lam, C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642–9.Google Scholar
Hood, JD, Meininger, CJ, Ziche, M, Granger, HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998;274:H1054–8.Google Scholar
Kroll, J, Waltenberger, J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998;252:743–6.Google Scholar
Ahmad, S, Hewett, PW, Wang, P, et al. Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis. Circ Res. 2006;99:715–22.Google Scholar
Maynard, SE. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–58.CrossRefGoogle ScholarPubMed
Levine, RJ, Maynard, SE, Qian, C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–83.Google Scholar
Inoue, N, Venema, RC, Sayegh, HS, Ohara, Y, Murphy, TJ, Harrison, DG. Molecular regulation of the bovine endothelial cell nitric oxide synthase by transforming growth factor-beta. Arterioscler Thromb Vascular Biol. 1995;15:1255–61.Google Scholar
Santibanez, JF, Letamendia, A, Perez-Barriocanal, F, et al. Endoglin increases eNOS expression by modulating Smad2 protein levels and Smad2-dependent TGF-beta signaling. J Cell Physiol 2007;210:456–68.Google Scholar
Sandrim, VC, Palei, ACT, Metzger, IF, Gomes, VA, Cavalli, RC, Tanus-Santos, JE. Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia. Hypertension 2008;52:402–7.Google Scholar
Chen, Z, Zhang, J, Stamler, JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USa 2002;99:8306–11.Google Scholar
Ramsay, B, de Belder, A, Campbell, S, Moncada, S, Martin, JF. A nitric oxide donor improves uterine artery diastolic blood flow in normal early pregnancy and in women at high risk of pre-eclampsia. Eur J Clin Invest 1994;24:76–8.Google Scholar
Grunewald, C, Kublickas, M, Carlström, K, Lunell, NO, Nisell, H. Effects of nitroglycerin on the uterine and umbilical circulation in severe preeclampsia. Obstet Gynecol. 1995;86:600–4.Google Scholar
Cetin, A, Yurtcu, N, Guvenal, T, Imir, AG, Duran, B, Cetin, M. The effect of glyceryl trinitrate on hypertension in women with severe preeclampsia, HELLP syndrome, and eclampsia. Hypertens Pregnancy 2004;23:37–46.Google Scholar
Manzur-Verástegui, S, Mandeville, PB, Gordillo-Moscoso, A, Hernández-Sierra, JF, Rodríguez-Martínez, M. Efficacy of nitroglycerine infusion versus sublingual nifedipine in severe pre-eclampsia: a randomized, triple-blind, controlled trial. Clin Exp Pharmacol Physiol 2008;35:580–5.CrossRefGoogle ScholarPubMed
Lees, C, Valensise, H, Black, R, et al. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol 2002;12:334–8.Google Scholar
Picciolo, C, Roncaglia, N, Neri, I. Nitric oxide in the prevention of pre-eclampsia. Prenat Neonatal Med 2000;5:212–5.Google Scholar
Cacciatore, B, Halmesmäki, E, Kaaja, R, Teramo, K, Ylikorkala, O. Effects of transdermal nitroglycerin on impedance to flow in the uterine, umbilical, and fetal middle cerebral arteries in pregnancies complicated by preeclampsia and intrauterine growth retardation. Am J Obstet Gynecol 1998;179:140–5.CrossRefGoogle ScholarPubMed
Trapani, A, Gonçalves, LF, Pires, MM de S. Transdermal nitroglycerin in patients with severe pre-eclampsia with placental insufficiency: effect on uterine, umbilical and fetal middle cerebral artery resistance indices. Ultrasound Obstet Gynecol 2011;38:389–94.Google Scholar
Luzi, G, Caserta, G, Iammarino, G, Clerici, G, Di Renzo, GC. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor. Ultrasound Obstet Gynecol 1999;14:101–9.CrossRefGoogle ScholarPubMed
Gori, T, Parker, JD. Nitrate Tolerance. A Unifying Hypothesis. Circulation 2002;106:2510–3.Google Scholar
Miller, MR, Megson, IL. Recent developments in nitric oxide donor drugs. Br J Pharmacol. 2009;151:305–21.Google Scholar
Davis, DG, Brown, PM. Re: glyceryl trinitrate (GTN) patches are unsuitable in hypertensive pregnancy. Aust N Z J Obstet Gynaecol 2001;41:474.Google Scholar
Thaler, I, Amit, A, Kamil, D, Itskovitz-Eldor, J. The effect of isosorbide dinitrate on placental blood flow and maternal blood pressure in women with pregnancy induced hypertension. Am J Hypertens. 1999;12:341–7.CrossRefGoogle ScholarPubMed
Martínez-Abundis, E, González-Ortiz, M, Hernández-Salazar, F, Huerta-J-Lucas, MT. Sublingual isosorbide dinitrate in the acute control of hypertension in patients with severe preeclampsia. Gynecol Obstet Invest 2000;50:39–42.Google Scholar
Nakatsuka, M, Takata, M, Tada, K, et al. A long-term transdermal nitric oxide donor improves uteroplacental circulation in women with preeclampsia. J Ultrasound Med 2002;21:831–6.Google Scholar
Thaler, I, Amit, A, Jakobi, P, Itskovitz-Eldor, J. The effect of isosorbide dinitrate on uterine artery and umbilical artery flow velocity waveforms at mid-pregnancy. Obstet Gynecol. 1996;88:838–43.Google Scholar
Makino, Y, Izumi, H, Makino, I, Shirakawa, K. The effect of nitric oxide on uterine and umbilical artery flow velocity waveform in pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1997;73:139–43.Google Scholar
Groten, T, Lehmann, T, Fitzgerald, J, et al. Reduction of preeclampsia related complications with with the NO-donor penterythriltetranitrat (PETN) in risk pregnancies – a prospective randomized double-blind placebo pilot study. Pregnancy Hypertens. 2012; Jul;2(3):181.Google Scholar
Immink, RV, van den Born, B-JH, van Montfrans, GA, Kim, Y-S, Hollmann, MW, van Lieshout, JJ. Cerebral hemodynamics during treatment with sodium nitroprusside versus labetalol in malignant hypertension. Hypertension 2008;52:236–40.CrossRefGoogle ScholarPubMed
National Institute for Health and Care Excellence (2010) Hypertension in Pregnancy. CG107. London: National Institute for Health and Care Excellence.Google Scholar
Sayed, N, Kim, DD, Fioramonti, X, Iwahashi, T, Duran, WN, Beuve, A. Nitroglycerin-induced S-nitrosylation and desensitization of soluble guanylyl cyclase contribute to nitrate tolerance. Circ Res 2008;103:606–14.CrossRefGoogle ScholarPubMed
Bryan, NS, Rassaf, T, Maloney, RE, et al. Cellular targets and mechanisms of nitros(yl)ation: an insight into their nature and kinetics in vivo. Proc Natl Acad Sci USa 2004;101:4308–13.Google Scholar
de Belder, AJ, MacAllister, R, Radomski, MW, Moncada, S, Vallance, PJ. Effects of S-nitroso-glutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 1994;28:691–4.Google Scholar
Ramsay, B, Radomski, M, de Belder, A, Martin, JF, Lopez-Jaramillo, P. Systemic effects of S-nitroso-glutathione in the human following intravenous infusion. Br J Clin Pharmacol 1995;40:101–2.Google Scholar
Langford, EJ, Brown, AS, Wainwright, RJ, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994;344:1458–60.Google Scholar
Langford, E, Wainwright, R, Martin, J. Platelet activation in acute myocardial infarction and unstable angina is inhibited by nitric oxide donors. Arterioscler Thromb Vasc Biol 1996;16:51–55.CrossRefGoogle ScholarPubMed
de Belder, A, Lees, C, Martin, J, Moncada, S, Campbell, S. Treatment of HELLP syndrome with nitric oxide donor. Lancet 1995;345:124–5.Google Scholar
Lees, C, Langford, E, Brown, AS, et al. The effects of S-nitrosoglutathione on platelet activation, hypertension, and uterine and fetal Doppler in severe preeclampsia. Obstet Gynecol 1996;88:14–9.Google Scholar
Everett, TR, Wilkinson, IB, Mahendru, AA, et al. S-Nitrosoglutathione improves haemodynamics in early-onset pre-eclampsia. Br J Clin Pharmacol 2014;78:660–9.Google Scholar
Hausvater, A, Giannone, T, Sandoval, Y-HG, et al. The association between preeclampsia and arterial stiffness. J Hypertens. 2012;30:17–33.Google Scholar
Martínez-Ruiz, A, Lamas, S. Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc Res 2007;75:220–8.Google ScholarPubMed
Kaposzta, Z, Clifton, A, Molloy, J, Martin, JF, Markus, HS. S-nitrosoglutathione reduces asymptomatic embolization after carotid angioplasty. Circulation 2002;106:3057–62.CrossRefGoogle ScholarPubMed
Zhou, A, Carrell, RW, Murphy, MP, et al. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010;468:108–11.Google Scholar
Rani, N, Dhingra, R, Arya, DS, Kalaivani, M, Bhatla, N, Kumar, R. Role of oxidative stress markers and antioxidants in the placenta of preeclamptic patients. J Obstet Gynaecol Res 2010;36:1189–94.Google Scholar
Knapen, MF, Mulder, TP, Van Rooij, IA, Peters, WH, Steegers, EA. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol 1998;92:1012–5.Google Scholar
Raijmakers, MT, Zusterzeel, PL, Steegers, EA, Hectors, MP, Demacker, PN, Peters, WH. Plasma thiol status in preeclampsia. Obstet Gynecol 2000;95:180–4.Google Scholar
Kaposzta, Z, Martin, JF, Markus, HS. Switching off embolization from symptomatic carotid plaque using S-nitrosoglutathione. Circulation 2002;105:1480–4.Google Scholar
Colagiovanni, DB, Borkhataria, D, Looker, D, et al. Preclinical 28-day inhalation toxicity assessment of s-nitrosoglutathione in beagle dogs and Wistar rats. Int J Toxicol 2011;30:466–77.Google Scholar
Facchinetti, F, Neri, I, Piccinini, F, et al. Effect of L-arginine load on platelet aggregation: a comparison between normotensive and preeclamptic pregnant women. Acta Obstet Gynecol Scand 1999;78:515–9.Google Scholar
Vadillo-Ortega, F, Perichart-Perera, O, Espino, S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011;342:d2901.Google Scholar
Neri, I, Monari, F, Sgarbi, L, Berardi, A, Masellis, G, Facchinetti, F. L-arginine supplementation in women with chronic hypertension: impact on blood pressure and maternal and neonatal complications. J Matern Fetal Neonatal Med 2010;23:1456–60.Google Scholar
Samangaya, RA, Mires, G, Shennan, A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia. Hypertens Pregnancy 2009;28:369–82.CrossRefGoogle ScholarPubMed
Ramesar, SV, Mackraj, I, Gathiram, P, Moodley, J. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats. Eur J Obstet Gynecol Reprod Biol 2011;157:136–40.Google Scholar
Herraiz, S, Pellicer, B, Serra, V, et al. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. BJOG 2012;119:1394–402.Google Scholar
Stanley, JL, Andersson, IJ, Poudel, R, et al. Sildenafil citrate rescues fetal growth in the catechol-O-methyl transferase knockout mouse model. Hypertension 2012;59:1021–8.Google Scholar
Nassar, AH, Masrouha, KZ, Itani, H, Nader, KA, Usta, IM. Effects of sildenafil in Nω-nitro-L-arginine methyl ester-induced intrauterine growth restriction in a rat model. Amer J Perinatol 2012;29:429–34.Google Scholar
Sharp, A, Cornforth, C, Jackson, R, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health 2018;2:93–102.Google Scholar
Colagiovanni, DB, Drolet, DW, Langlois-Forget, E, Piché, M-P, Looker, D, Rosenthal, GJ. A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma. Regul Toxicol Pharmacol 2012;62:115–24.Google Scholar